A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Clinical trial NCT04839510 · UNKNOWN

Trial details

NCT number: NCT04839510
Sponsor: Shanghai Miracogen Inc.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced Urothelial Cancer Metastatic Urothelial Carcinoma

Start date: 2021-04-20
Primary completion: 2022-06-01
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.